Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Fans don't think that the two colors in the Super Bowl 2025 logo — red and green — are a coincidence Skyler Caruso is a Writer and Reporter of PEOPLE Digital Entertainment. She joined PEOPLE ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

In particular, Lilly highlighted the momentum behind breast cancer med Verzenio and the SGLT2 inhibitor Jardiance, which generated roughly $1.6 billion and $1.2 billion in 2024’s fourth quarter ...

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Revenue from the breast cancer treatment Verzenio also helped, climbing 36% to $1.55 billion. Overall, Lilly’s quarterly profit swelled to $4.41 billion. Revenue advanced 45% to $13.53 billion ...

Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...